Full Press Release Details
Good afternoon and welcome to Aditxt, Inc.'s online business
update and townhall meeting with Amro Albanna, Co-Founder & CEO. The meeting will include, but is not limited to, commentary on the
following topics: A business update and upcoming milestones, a summary and discussion of revenue strategy, an overview of the acquisition
strategy. The presentation will be followed by a Q&A. As a reminder, this webinar is being recorded today, January 18th, 2022. We
have compiled questions that were submitted ahead of time and will be asking them on today's webinar. If you have a question during
the presentation, please submit it using the Q&A box provided. We will try to get to all questions if time permits. I will now turn
the call over to Amro Albanna to provide introduction and commentary on the Safe Harbor Statement & Disclaimers. Thank you.
Great. Thank you very much, Max, I appreciate you helping us set this
up. Good morning, everyone. Good afternoon. And good evening. We really appreciate you taking time to come in and listen to the Aditxt
update and our business update for shareholders. But more importantly, we're very much interested in hearing from you and answering the
questions that were submitted already. But as Max mentioned, the forum is open for new questions. And I do encourage you to send questions
as I present or even during the Q&A, as we as a team are very interested in helping our shareholders and future shareholders to better
understand Aditxt and our strategy moving forward. So, a couple logistical questions before we begin, Max, if you don't mind, just one
more time give the instruction to those who want to submit questions during the presentation.
Absolutely, Amro. If you do have a question today, please submit it
doing so using the Q&A box provided. I'll then be able to moderate those questions following the presentation and during the Q&A
portion of the webinar.
Wonderful. Thank you again, Max. So safe harbor statement disclaimers.
Many if not all of you are familiar with this legal disclaimer and legal statement. It is important however, for me to just make couple
comments. In order for us as a company to be able to go out as a public company to go out to be able to go out and share and discuss our
business strategy. We may provide forward looking statements. So, I want to make sure that we take just a little bit of time going through
this slide. And I want to remind everyone, those who have been following us and those who are new to Aditxt, we are still in the process
of an M&A process with AiPharma. That is not concluded yet. And I will discuss that in more details as we go through the presentation.
And we also provided and announced a letter of intent to acquire a diagnostic company that's focused on point of care. So just keep those
couple things in mind as we go through it. Some of the statements will be forward looking statements just given the nature of this forum.
And the fact that we are still going through the M&A process with couple of companies including AiPharma. Next slide, please Max.
Our agenda today, I will make brief remarks as far as the status of our business and what we are focused on when it comes to 2022. Basically,
revenue and growth strategy. And we will jump right into Q&A. I don't have this item on the agenda. But I will also make at the very
end of the presentation, some of my own remarks regarding the stock. So, let's begin with revenue and growth strategy for 2022. In order
for it to, to make sense, we got to begin with understanding what Aditxt is as a business and what our mission is. So just about 18 months
ago, when we took Aditxt public, we wanted to make sure that we are uniquely positioned in terms of developing technologies focused on
improving the health of the immune system. That's been our mission. That's been our vision. In order for us to capture that uniqueness
and execute on that vision, we can't only look at the immune system. We have to include the pathogen side or the threat side to our immune
systems. Not to mention COVID once again, which has been a subject of conversation for the past couple of years, but COVID really has
highlighted the critical nature and the critical need for approaching the health of our immune system in a holistic fashion, a 360 view
of our immune system, which addresses the threat to our immune system, as well as our level of readiness to address that threat. So as
you can see on the slide, we have four segments of our business of Aditxt. The first segment is threat detection, we are focused on developing
new innovations that allows us to detect threats, including viruses, including bacteria, including parasites, ahead of time and point
of care technologies are advancing every single day. And we are on the lookout for those technologies that would help us deploy point
of care, detection, pathogen detection technologies to the marketplace. The second segment on its right, is the anti-viral side of things,
that threat elimination, we talked about AiPharma, and how strategic AiPharma is for us to begin to enter the marketplace of anti-viral
and our ability to deploy technology platforms such as favipiravir, into the pathogen elimination segments, or the anti-viral segments.
Switching over to the immune side, there are a couple pieces that are needed when it comes to our immune system and the health of the
immune system. The first component, we have to have the ability to monitor the status of our immune system to understand its level of
readiness when it comes to a particular threat. And finally, the immune modulation piece, which is the therapeutic space, it is the ability
to modulate the immune system to retrain the immune system to make it behave in a certain way.
So, understanding the foundation of Aditxt understanding the unique
position of Aditxt, and how would you; what would be considered an effective approach to immune health? We've designed the business we've
architected the business with those four segments in mind. And that's what we've been doing. And that's what we've been doing in the last
18 months laying the foundation for a business that takes a 360 view to immune health. Now the question is all about execution. And in
2022, speaking to the team, we are focused on transitioning Aditxt's story from a great story, which you've probably heard me say
that before, to a growth story. So Max, if you don't mind just undoing the last three [slides], only the one on the threat detection.
If you can, if not no worry. So, starting with threat detection, we are equipped to handle PCR testing, it is no secret that PCR testing,
there is great demand for PCR testing, there is a lot of overflow coming from labs all over the country. And we are currently starting
to process PCR testing in our Richmond, Virginia facility, that is number one activity that we are doing when it comes to threat detection.
And when it comes to revenue generation for Aditxt, the number two and number three, we announced a letter of intent to acquire a company
that is focused on developing point of care devices focused on early detection starting with rapid antigen tests. This is where we have
to go back to that forward looking statement. It is an LOI, it is a non binding, we are still working on it. But it is not completed at
this time. Our interest in this company begins with the team. It is a team that understands point of care, understands early detection,
and more importantly shares the same mission and the same vision. And they understand the critical nature of having early detection as
part of the equation that we provide as Aditxt. And we are currently working diligently on the LOI to convert that into a definitive agreement.
If that does go through that will give us yet an additional opportunity into the detection space. When it comes to revenues. The rapid
antigen test was already submitted for EUA they are continuing to work on additional data that is required. And if they receive EUA approval
that would give Aditxt pretty significant opportunity when it comes to revenue generation in you know, in in 2022 and I certainly do not
want to predict whether or not they're going to secure their EUA. And if they do, whether or not or when they will secure it however,
they are, they certainly from our point of view, they meet many of the criteria the regulatory agencies are looking for, especially with
the current demand that it's on the market. But it really doesn't stop with rapid antigen. Our interest and our working with them would
go way beyond rapid antigen, we're looking at other products, including celiac for allergies, ovarian cancer, prostate cancer, and others
that will be part of this transaction, if and when we close it. Switching over to pathogen elimination or the deactivation of the pathogen.
It is important that we have a strategy in place as Aditxt where we have technology platforms ready to be deployed in the market when
it comes to anti-viral. Anti-viral has been a topic of discussion, certainly because of COVID-19. We started working with AiPharma, probably
about six to eight months ago. AiPharma has a couple of products right now. The first one which is in the market, Avigan 200. It's an
international market globally outside the US, it has been it went through multiple clinical trials, multiple approvals, including EUA's,
compassionate use, as well as full approval, and according to AiPharma
and these are the public statements obviously, they would have to make and it would be more appropriate for them to make, they have been
generating, what we would consider, significant revenues in 2021. For the Avigan 200 formulation, moving forward, they are working on
the Qifenda 400. Again, based on the favipiravir molecule, but it's a different formulation. It's a different concentration. And they
are continuing to work on the regulatory strategy above and beyond international markets. We allknow, many of you know that the last clinical
trial did not go as well as we hoped, but they are taking many steps to revisit the strategy of reentering into the US. Again, it is important
to mention which I know this is probably something an area of confusion. The AiPharma deal has an initial closing, followed by secondary
closing. With the current agreement we have in place the secondary closing would require shareholders' approval, which will have
to be preceded by a proxy, a massive document to share with the shareholders. Why AiPharma, and the details about AiPharma before we can
secure secondary closing. Before I move on to the third aspect of Aditxt, I want to mention something with AiPharma. Similar to the POC
(point of care) company, AiPharma and AiPharma's team, incredible team sophisticated team continues to look for new innovations
and new platforms. We've been working every single day, helping us introduce us to other channels that they're currently in. So, there
is a strategic value of working with AiPharma and their team above and beyond the initial two products that they bring to the table right
now. Switching over to immune monitoring. Key Area. The world for the past couple of years has been focused on infection status when it
comes to COVID. We all we all know what PCR testing is we all know what rapid antigen testing is. But reality, if we are going to have
a full solution, we have to combine infection status with protection status, we have to understand someone's immunity status to COVID-19.
And its variant, the timing could not be better for a platform like AditxtScore where we can deploy it and scale to begin to understand
someone's immune response and whether or not they have developed sufficient immune response to COVID. Look at what's happening right now.
Many or some people that were vaccinated there getting omicron they don't understand why and AditxtScore is going to play a critical role
for our understanding of how our immune system and the level of its immune response to a particular pathogen. One of the questions that
I get asked, how come AditxtScore has not gained traction in the last few months? And that's a fair question. If you look at the process,
and the timeline, we launched our CLIA and CAP center, July 2021. So that's just about six months ago, we worked on our regulatory requirements,
which is CLIA and CAP, we secured, and we became a licensed Medicare company or provider. And I believe that was in October, and the question
remains, how come we're not getting the traction that we all would be hoping for, in any new innovation, and like PCR and rapid antigen
tests, which is required by governments in any new innovation, it will require creating awareness, which is what we are working on right
now, the right partners to bring in the right partners, the right execution partners, the right global partners, to make sure that we
begin launching AditxtScore at a scale, because it is the right time for a product like AditxtScore, starting with COVID-19. And of course,